Cargando…

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection of AR mutations that convert anti-androgens to agon...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Neill, Daniel, Jones, Dominic, Wade, Mark, Grey, James, Nakjang, Sirintra, Guo, Wenrui, Cork, David, Davies, Barry R., Wedge, Steve R., Robson, Craig N., Gaughan, Luke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694883/ https://www.ncbi.nlm.nih.gov/pubmed/26267320

Ejemplares similares

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2015)

Differential regulation of the androgen receptor by protein phosphatase regulatory subunits
por: Grey, James, et al.
Publicado: (2017)

Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity
por: McClurg, Urszula L., et al.
Publicado: (2017)

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
por: Kounatidou, Evangelia, et al.
Publicado: (2019)

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2017)

Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells
por: Logan, Ian R., et al.
Publicado: (2016)

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival
por: McClurg, Urszula L., et al.
Publicado: (2018)

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
por: Gaughan, Luke, et al.
Publicado: (2005)

Correction to ‘Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation’
por: Gaughan, Luke, et al.
Publicado: (2021)

The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover
por: Coffey, Kelly, et al.
Publicado: (2013)

Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway
por: McClurg, Urszula L., et al.
Publicado: (2014)

KDM4B is a Master Regulator of the Estrogen Receptor Signalling Cascade
por: Gaughan, Luke, et al.
Publicado: (2013)

Plasma Membrane-Located Purine Nucleotide Transport Proteins Are Key Components for Host Exploitation by Microsporidian Intracellular Parasites
por: Heinz, Eva, et al.
Publicado: (2014)

The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer
por: Wade, Mark A., et al.
Publicado: (2015)

Regulation of the androgen receptor by SET9-mediated methylation
por: Gaughan, Luke, et al.
Publicado: (2011)

Regulation of the androgen receptor by SET9-mediated methylation
por: Gaughan, Luke, et al.
Publicado: (2013)

Transport proteins of parasitic protists and their role in nutrient salvage
por: Dean, Paul, et al.
Publicado: (2014)

A Novel Extracellular Metallopeptidase Domain Shared by Animal Host-Associated Mutualistic and Pathogenic Microbes
por: Nakjang, Sirintra, et al.
Publicado: (2012)

CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration-Resistant Prostate Cancer
por: Alebady, Zainab A. H., et al.
Publicado: (2023)

Patterns of prokaryotic lateral gene transfers affecting parasitic microbial eukaryotes
por: Alsmark, Cecilia, et al.
Publicado: (2013)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
por: Bhoir, Siddhant, et al.
Publicado: (2023)

SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells
por: O'Neill, Daniel J, et al.
Publicado: (2014)

The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer
por: Jones, Dominic, et al.
Publicado: (2019)

Engineering prostate cancer in vitro: what does it take?
por: Buskin, Adriana, et al.
Publicado: (2023)

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
por: Liu, Huiqin, et al.
Publicado: (2022)

Identification of TIAM1 as a Potential Synthetic-Lethal-like Gene in a Defined Subset of Hepatocellular Carcinoma
por: Permtermsin, Chalermsin, et al.
Publicado: (2023)

Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma
por: Noble, Richard A., et al.
Publicado: (2017)

Identification of Novel Androgen-Regulated Pathways and mRNA Isoforms through Genome-Wide Exon-Specific Profiling of the LNCaP Transcriptome
por: Rajan, Prabhakar, et al.
Publicado: (2011)

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer
por: Han, Wanting, et al.
Publicado: (2022)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment
por: Alexandrova, EM, et al.
Publicado: (2015)

Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53
por: Joerger, Andreas C., et al.
Publicado: (2015)

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
por: Issa, Hasan, et al.
Publicado: (2023)

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma
por: Reyes-Uribe, Patricia, et al.
Publicado: (2018)

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients
por: Sugawara, Tatsuo, et al.
Publicado: (2016)

Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants
por: An, Jian, et al.
Publicado: (2014)

Reduction and Expansion in Microsporidian Genome Evolution: New Insights from Comparative Genomics
por: Nakjang, Sirintra, et al.
Publicado: (2013)

A Recent Whole-Genome Duplication Divides Populations of a Globally Distributed Microsporidian
por: Williams, Tom A., et al.
Publicado: (2016)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ar4ffvea8lsclvlaeiotpo6vuq